Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yoshiko Takeuchi

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Internal Medicine (Tokyo, Japan)|April 3, 2015
Dapsone hypersensitivity syndrome-related lung injury without eosinophilia in the bronchoalveolar lavage fluidYuhei Kinehara, Takashi Kijima, Koji Inoue, et al.
BMC Pulmonary Medicine|November 5, 2014
Development of microscopic polyangiitis-related pulmonary fibrosis in a patient with autoimmune pulmonary alveolar proteinosisYuhei Kinehara, Hiroshi Kida, Yoshikazu Inoue, et al.
Lung Cancer (Amsterdam, Netherlands)|January 21, 2015
Favorable response to trastuzumab plus irinotecan combination therapy in two patients with HER2-positive relapsed small-cell lung cancerYuhei Kinehara, Toshiyuki Minami, Takashi Kijima, et al.
Nature Communications|April 4, 2024
VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 responseThomas Thisted, F Donelson Smith, Arnab Mukherjee, et al.
The Journal of Experimental Medicine|November 10, 2019
Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cellsAtsushi Tanaka, Hiroyoshi Nishikawa, Shinsuke Noguchi, et al.
Cell|August 14, 2020
TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 ImmunotherapyMartina Molgora, Ekaterina Esaulova, William Vermi, et al.
Science Immunology|November 12, 2021
Highly immunogenic cancer cells require activation of the WNT pathway for immunological escapeYoshiko Takeuchi, Tokiyoshi Tanegashima, Eiichi Sato, et al.
Biorxiv : the Preprint Server for Biology|April 17, 2026
Immune Checkpoint Therapy Drives Maturation of a Cellular Neighborhood Nucleated by T Cell-APC Triads Enabling Spatially Compartmentalized Tumor ImmunityRuan F V Medrano, Vladimir Sukhov, Kevin Hoffer-Hawlik, et al.
Nature Immunology|September 2, 2020
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapiesShogo Kumagai, Yosuke Togashi, Takahiro Kamada, et al.
Nature|July 24, 2024
Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapyHussein Sultan, Yoshiko Takeuchi, Jeffrey P Ward, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Internal Medicine (Tokyo, Japan)|April 3, 2015
Dapsone hypersensitivity syndrome-related lung injury without eosinophilia in the bronchoalveolar lavage fluidYuhei Kinehara, Takashi Kijima, Koji Inoue, et al.
BMC Pulmonary Medicine|November 5, 2014
Development of microscopic polyangiitis-related pulmonary fibrosis in a patient with autoimmune pulmonary alveolar proteinosisYuhei Kinehara, Hiroshi Kida, Yoshikazu Inoue, et al.
Lung Cancer (Amsterdam, Netherlands)|January 21, 2015
Favorable response to trastuzumab plus irinotecan combination therapy in two patients with HER2-positive relapsed small-cell lung cancerYuhei Kinehara, Toshiyuki Minami, Takashi Kijima, et al.
Nature Communications|April 4, 2024
VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 responseThomas Thisted, F Donelson Smith, Arnab Mukherjee, et al.
The Journal of Experimental Medicine|November 10, 2019
Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cellsAtsushi Tanaka, Hiroyoshi Nishikawa, Shinsuke Noguchi, et al.
Cell|August 14, 2020
TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 ImmunotherapyMartina Molgora, Ekaterina Esaulova, William Vermi, et al.
Science Immunology|November 12, 2021
Highly immunogenic cancer cells require activation of the WNT pathway for immunological escapeYoshiko Takeuchi, Tokiyoshi Tanegashima, Eiichi Sato, et al.
Biorxiv : the Preprint Server for Biology|April 17, 2026
Immune Checkpoint Therapy Drives Maturation of a Cellular Neighborhood Nucleated by T Cell-APC Triads Enabling Spatially Compartmentalized Tumor ImmunityRuan F V Medrano, Vladimir Sukhov, Kevin Hoffer-Hawlik, et al.
Nature Immunology|September 2, 2020
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapiesShogo Kumagai, Yosuke Togashi, Takahiro Kamada, et al.
Nature|July 24, 2024
Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapyHussein Sultan, Yoshiko Takeuchi, Jeffrey P Ward, et al.
Pageof 3